MREO
Mereo Biopharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Ample Liquidity
High Gross Profit Margin
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MREO
Mereo Biopharma Group Plc
A clinical stage biopharmaceutical company focused on rare diseases and oncology
Pharmaceutical
03/10/2015
04/24/2019
NASDAQ Stock Exchange
36
12-31
Depository Receipts (Ordinary Shares)
One Cavendish Place, 4th Floor, London W1G 0QF, United Kingdom
--
Mereo BioPharma Group plc was incorporated under the laws of England and Wales on March 10, 2015. Mereo is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies aimed at improving the therapeutic outcomes for patients with rare diseases. Mereo's portfolio includes four clinical stage product candidates, each from a large pharmaceutical company. Mereo is developing BPS-804 for the treatment of osteogenesis imperfecta (" OI "), MPH-966 for the treatment of severe α-1 antitrypsin deficiency (" AATD "), BCT-197 for the treatment of acute exacerbation of chronic obstructive pulmonary disease (" AECOPD ") and BGS-649 for the treatment of hypogonadotropic hypogonadism (" HH ") in obese men.
Company Financials
EPS
MREO has released its 2025 Q3 earnings. EPS was reported at -0.01, versus the expected 0, missing expectations. The chart below visualizes how MREO has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
